Nomura Holdings’s Charles River Laboratories CRL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
Sell
-1,112,400
Closed -$169M 1904
2025
Q2
$169M Buy
1,112,400
+512,400
+85% +$68.3M 0.35% 53
2025
Q1
$90.3M Buy
+600,000
New +$101M 0.17% 91
2024
Q3
Sell
-28,600
Closed -$5.91M 1605
2024
Q2
$5.91M Sell
28,600
-1,400
-5% -$317K 0.01% 621
2024
Q1
$8.13M Buy
+30,000
New +$7.16M 0.02% 505

Other funds holding CRL

Nomura Holdings's CRL Position: Q2 2026 in Review

Nomura Holdings increased its Charles River Laboratories (CRL) stake by 1,806% in Q2 2026, buying an estimated $14.6M and bringing the position to 86,744 shares worth $19.7M. The position accounts for 0.02% of the portfolio, ranked #366.

Nomura Holdings first reported a position in CRL in Q2 2013 and has held it in 26 quarters since. The position peaked at $238M in Q2 2025. 570 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

  • Nomura Holdings held 86,744 shares of Charles River Laboratories worth $19.7M as of Q2 2026.
  • Nomura Holdings bought 82,194 Charles River Laboratories shares in Q2 2026, an estimated $14.6M.
  • Charles River Laboratories made up 0.02% of Nomura Holdings's portfolio in Q2 2026, its #366 holding.
  • Nomura Holdings first reported a position in Charles River Laboratories in Q2 2013 and has held it in 26 quarters since.
  • Nomura Holdings's Charles River Laboratories position peaked at $238M in Q2 2025.
  • 570 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on Nomura Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.